Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents
Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Skinvisible Pharmaceuticals publishes groundbreaking research on transdermal obesity drug delivery using Invisicare technology. The study shows 99.6% transdermal penetration of GLP-1 actives, offering a non-invasive alternative to injections. Skinvisible seeks partnerships to bring transdermal obesity therapies to market.
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Pharmaceuticals announces breakthrough data on transdermal obesity drug delivery using Invisicare technology. Studies show up to 69% drug penetration, offering a non-invasive alternative to injections. Skinvisible seeks partners to bring transdermal obesity therapies to market.
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Skinvisible Pharmaceuticals expands its obesity patent application for transdermal drug delivery using Invisicare technology. The innovation enhances systemic absorption of GLP-1 agonists, CB-1 antagonists, and SGLT-2 inhibitors, offering a needle-free alternative. Skinvisible seeks partners to bring this breakthrough to market.
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals files a provisional patent for transdermal obesity drug delivery using Invisicare technology. This needle-free, topical solution enhances drug absorption and patient compliance, revolutionizing obesity treatment. Skinvisible seeks partners to bring this innovation to market.
Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV – February 14, 2024 – Skinvisible, Inc. (“Skinvisible”) (OTCQB: SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ: QNRX). The trials focus on the innovative formulation “QRX003,” powered by Skinvisible’s Invisicare® proprietary drug delivery technology, to address the challenges […]
